GlassScriptPhysician profile
Michelle A Duplain
NPI 1144312422
$3,586.84
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,153 · 2022: $776 · 2023: $644 · 2024: $13.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.04 | 2021-2024 | |
| Novo Nordisk INC | $624.98 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $293.99 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.27 | 2021-2023 | Ofev |
| Glaxosmithkline, LLC. | $161.85 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $151.24 | 2023 | Quviviq |
| Lilly USA, LLC | $118.37 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Corcept Therapeutics | $111.85 | 2021 | |
| Astellas Pharma US INC | $106.26 | 2021-2023 | Veozah |
| Almatica Pharma LLC | $104.14 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Astrazeneca Pharmaceuticals LP | $94.89 | 2021-2023 | Breztri |
| Merck Sharp & Dohme LLC | $80.74 | 2021-2022 | |
| Pfizer INC. | $62.06 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $46.42 | 2022 | |
| Exact Sciences Corporation | $40.72 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $36.61 | 2023 | |
| Ibsa Pharma INC. | $29.08 | 2021-2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $28.70 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.74 | 2023 | Jornay Pm |
| Vbi Vaccine (Delaware) INC. | $17.65 | 2022 | |
| Eisai INC. | $15.50 | 2021 | |
| Adlon Therapeutics L.P. | $15.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.58 | 2021 | |
| Seqirus USA INC | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Duplain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.